ALLOGENE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.5 USD | +1.63% |
|
-0.79% | -22.12% |
| 05-31 | Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target | MT |
| 05-21 | Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating | MT |
Presenter SpeechMatthew Holt (Analysts)Good afternoon, everyone. My name is Matthew Holt, and ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Calendar
05/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2.5
USD
Average target price
11.32
USD
Spread / Average Target
+352.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.12% | 522M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Transcript : Allogene Therapeutics, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-08-2019 01
